A 63-Year-Old Man with Myelofibrosis

Stephen T. Oh, MD, PhD, presents the case of a 63-year-old man previously diagnosed and treated with primary myelofibrosis.

An expert on myelofibrosis discusses how to determine whether a patient is experiencing ruxolitinib failure or disease progression and provides insights on when to intervene or change therapy.

Dr Oh provides clinical insights on sequencing therapies for patients with myelofibrosis and discusses the sequential use of JAK inhibitors.

A myelofibrosis specialist discusses his approach to monitoring treatment response in patients with myelofibrosis.

Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.

An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.

Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.

Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.